BRO

New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk

Harvard Medical School Contributing Editor Atherosclerosis is the fundamental process in coronary artery disease, stroke, and many other vascular diseases. It is responsible for more than half of the disease burden of the United States, with an annual cost of over $100 billion. This includes over 1.5 million my...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...

Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused oninfectious disease and dermatology, today announced thatresearchers at the University of Pennsylvania led by Dr. PaulJanmey and Dr. Robert Bucki, in collaboration with Dr. Paul B.Savage of Brigham Young University, have demonstrated in a seriesof in vitro experiments tha...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Gentium's Defibrotide Seen as Active in Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq:GENT) announced the presentation of both clinical and preclinicaldata that support the safety, activity, synergy and potentialmechanism of action of Defibrotide in combination with anticancertherapy in multiple myeloma. Investigators presented both an updatefrom the Company's ongoing Phase I/II clinical trial for patientswith...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control andReducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in conjunction with its commercialization partner S2 Therapeutics,Inc., reported today the results of its Phase IIIb clinical trialsupporting the overall and cardiovascular safety of Cycloset(TM) (Aquick release for...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. today announced that data featuring itsapproved diabetes drugs, BYETTA(R) (exenatide) injection andSYMLIN(R) (pramlintide acetate) injection, and its pipelinecandidates will be presented at the American Diabetes Association's(ADA) 67th Annual Scientific Sessions being held in Chicago, ILfrom June 22 to 26. The...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- QuigleyPharma, <a target="_blank" href="http://www.quigleypharma.com/">www.QuigleyPharma.com , a whollyowned subsidiary of The Quigley Corporation announced today that ithas completed a follow-up study to evaluate the impact of QR-443 onlevels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in acachexia model. This new data...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...

PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference

MUNICH, Germany, June 14, 2007 /PRNewswire/ -- PARI Pharma willpresent in-vivo study results for their PARI SINUS pulsating drugdelivery system as well as lung deposition and pharmacokinetic dataof their proprietary inhaled liposomal Ciclosporin A formulation inlung transplant patients at the European Cystic Fibrosis Conference(ECFC) in Belek, Turkey this week. Continuing their tra...

Gabapentin Shown Effective for Fibromyalgia Pain

BETHESDA, Md., June 11, 2007--New research supported by theNational Institutes of Healths National Institute of Arthritis andMusculoskeletal and Skin Diseases (NIAMS) shows that theanticonvulsant medication , which is used for certaintypes of seizures, can be an effective treatment for the pain andother symptoms associ...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

- Data presented at 12th Congress of European Hematology - CHESHIRE, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- AlexionPharmaceuticals, Inc. today announced results from three analysesof Phase III studies examining Soliris(TM) (eculizumab) for thetreatment of paroxysmal nocturnal hemoglobinuria (PNH) at the 12thCongress of European Hematology, organized by The EuropeanHematology Assoc...

Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

COPENHAGEN, June 3, 2007 - Genmab A/S (CSE: GEN) announcedtoday pre-clinical data illustrating its fully humanHuMax-EGFr™ (zalutumumab) antibody may have broad potentialto treat cancers that over-express several types of EGFr (epidermalgrowth factor receptor). Recently, mutations which appear to alter the signaling abilityof EGFr have been identified in tumors from lung canc...

Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that its Phase IIIAIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation forthe treatment of people with cystic fibrosis (CF) who havepulmonary Pseudomonas aeruginosa (P. aeruginosa) met its primaryefficacy endpoint of change at Day 28 from baseline in respiratorysymptoms, as assess...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome

NEW YORK, May 22, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and Cypress Bioscience, Inc. today announcedthat preliminary top-line results from a 1,196 patient randomized,three month, double-blind, placebo-controlled pivotal Phase IIIstudy demonstrate statistically significant therapeutic effects ofmilnacipran as a treatment of fibromyalgia syndrome. At this timethe companie...

FDA Announces Audio Broadcasts on Emerging Drug Safety Information

ROCKVILLE, Md., April 20,2007-The U.S. Food and DrugAdministration (FDA) is alerting health care professionals andconsumers to the availability of audio broadcasts that provideemerging drug safety information. The broadcasts, commonly known aspodcasts, can be transmitted to personal computers and personalaudio players. The service is part of the agency's ongoing effort to broadena...

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patientstreated with Pfizer's Lyrica reduced their pain by 50 percent ormore compared with placebo, according to study results presentedtoday at the American Academy of Neurology annual meeting.Clinically, this outcome would equate to a patient with severe painreporting a reduction to mild to moderate pain. Fibromyalgia is one of t...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

Gentium's Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 23, 2007 -Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported thatits lead product, Defibrotide, will be the subject of a posterpresentation at the World Congress of Nephrology 2007 being held inRio de Janeiro, Brazil from April 21-25, 2007. On Monday, April 23, 2007, Cinara Echart, Ph.D., Manager ofBiological Research Laboratory...

Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

SEATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Sciences, Inc.(Nasdaq:GILD) today announced detailed results of its Phase IIIAIR-CF2 study evaluating aztreonam lysine for inhalation, anantibiotic, in patients with cystic fibrosis (CF) who havepulmonary Pseudomonas aeruginosa (P. aeruginosa). In the study, a28-day treatment course of aztreonam lysine significantly improvedthe time to need fo...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immuneresponse data from two previously conducted Phase 2 clinical trialsof GVAX immunotherapy for prostate cancer. Evaluation of antibodyresponses in patients with advanced prostate cancer from thesestudies shows that the GVAX cell-based immunotherapy inducesantibody responses to a bro...

Gentium's Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 13, 2007 -Gentium, S.p.A. (NASDAQ:GENT) (the "Company") today reported thatits lead investigational product, Defibrotide, will be the subjectof two poster presentations at the American Association for CancerResearch's (AACR) Annual Meeting being held at the Los AngelesConference Center in Los Angeles, California, from April 14-18,2007. On...

Repros' Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) announced final results of a U.S.Phase 2 study of Proellex(TM), an oral drug being developed torelieve symptoms of uterine fibroids. This study suggests thattreatment with Proellex results in a statistically highlysignificant improvement in symptoms associated with uterinefibroids and is generally w...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

Research from Non-clinical Studies Presented at the TargetedAnticancer Therapies (TAT 2007) and the Keystone Symposia MolecularTargets for Cancer Meetings Support Phase 1 Trial Design SOUTH SAN FRANCISCO, Calif., March 20, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , presentednon-clinical data on its development-stage compound, SNS-314, attwo leading scientific meetings f...

MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy

MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.(NASDAQ: MOGN), a biopharmaceutical company focused in oncology andacute care, today announced that a randomized, double-blind,multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection for sedation of patients undergoingbronchoscopy successfully met its primary endpoint of sedationsuccess as well as all sec...

AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

VIENNA, Austria and CHAPEL HILL, N.C., US, March 06, 2007/PRNewswire/ -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") andLantibio, Inc. ("Lantibio") today announced positive final resultsfrom their placebo controlled, double-blinded Phase II clinicalstudy of Moli1901, an experimental compound to treat cysticfibrosis ("CF"). Moli1901 is being developed by AOP Orphan inEurope under a licen...